Addex Therapeutics Ltd - Product Pipeline Review - 2014

Published: Sep, 2014 | Pages: 57 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Addex Therapeutics Ltd - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Addex Therapeutics Ltd - Product Pipeline Review - 2014', provides an overview of the Addex Therapeutics Ltd's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Addex Therapeutics Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Addex Therapeutics Ltd including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Addex Therapeutics Ltd's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Addex Therapeutics Ltd's pipeline products

Reasons to buy

- Evaluate Addex Therapeutics Ltd's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Addex Therapeutics Ltd in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Addex Therapeutics Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Addex Therapeutics Ltd and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Addex Therapeutics Ltd
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Addex Therapeutics Ltd and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Addex Therapeutics Ltd Snapshot 6
Addex Therapeutics Ltd Overview 6
Key Information 6
Key Facts 6
Addex Therapeutics Ltd - Research and Development Overview 7
Key Therapeutic Areas 7
Addex Therapeutics Ltd - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
Addex Therapeutics Ltd - Pipeline Products Glance 16
Addex Therapeutics Ltd - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Addex Therapeutics Ltd - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Addex Therapeutics Ltd - Drug Profiles 20
dipraglurant IR 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
ADX-71441 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
ADX-63365 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
ADX-68692 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ADX-71743 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
ADX-88178 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ADX-92639 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
dipraglurant ER 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecule to Agonize GABAB Receptor for Overactive Bladder and Pain 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule to Inhibit FSHR/LHR For Sex Hormone Dependent Tumors 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules to Inhibit mGluR2 for Central Nervous System Disorders 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecules to Inhibit mGluR7 For Central Nervous System Disorders 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ADX-85142 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ADX-90125 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ADX-94819 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ADX-95477 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecule to Agonize A2A for Immunology, Hematological and Neurological Disorders 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecule to Agonize GLP-1R For Type 2 Diabetes 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecule to Inhibit IL1R1 for Metabolic Disorders 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules to Agonize TRKB for Neurodegenerative Diseases 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecules to Inhibit TNFR1 for Immunology, Gastrointestinal, Neurology and Hematological Disorders 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Addex Therapeutics Ltd - Pipeline Analysis 41
Addex Therapeutics Ltd - Pipeline Products by Target 41
Addex Therapeutics Ltd - Pipeline Products by Route of Administration 43
Addex Therapeutics Ltd - Pipeline Products by Molecule Type 44
Addex Therapeutics Ltd - Pipeline Products by Mechanism of Action 45
Addex Therapeutics Ltd - Recent Pipeline Updates 46
Addex Therapeutics Ltd - Dormant Projects 52
Addex Therapeutics Ltd - Discontinued Pipeline Products 53
Discontinued Pipeline Product Profiles 53
ADX-10059 53
ADX-10061 53
ADX-71943 53
Small Molecules to Antagonize Adenosine A3 for Glaucoma 53
Addex Therapeutics Ltd - Company Statement 54
Addex Therapeutics Ltd - Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 57
Disclaimer 5

List of Tables
Addex Therapeutics Ltd, Key Information 6
Addex Therapeutics Ltd, Key Facts 6
Addex Therapeutics Ltd - Pipeline by Indication, 2014 9
Addex Therapeutics Ltd - Pipeline by Stage of Development, 2014 12
Addex Therapeutics Ltd - Monotherapy Products in Pipeline, 2014 13
Addex Therapeutics Ltd - Out-Licensed Products in Pipeline, 2014 14
Addex Therapeutics Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2014 15
Addex Therapeutics Ltd - Phase II, 2014 16
Addex Therapeutics Ltd - Phase I, 2014 17
Addex Therapeutics Ltd - Preclinical, 2014 18
Addex Therapeutics Ltd - Discovery, 2014 19
Addex Therapeutics Ltd - Pipeline by Target, 2014 42
Addex Therapeutics Ltd - Pipeline by Route of Administration, 2014 43
Addex Therapeutics Ltd - Pipeline by Molecule Type, 2014 44
Addex Therapeutics Ltd - Pipeline Products by Mechanism of Action, 2014 45
Addex Therapeutics Ltd - Recent Pipeline Updates, 2014 46
Addex Therapeutics Ltd - Dormant Developmental Projects,2014 52
Addex Therapeutics Ltd - Discontinued Pipeline Products, 2014 53
Addex Therapeutics Ltd, Subsidiaries 55